Repros gets partial reprieve on Proellex hold
This article was originally published in Scrip
Executive Summary
The US FDA reclassified the clinical hold on Repros Therapeutics' studies for its orally selective progesterone antagonist Proellex from a full hold to partial status to permit the firm to conduct a Phase II study to test lower doses of the medicine in patients with endometriosis, a condition which affects about 5 million women of reproductive age in the US and Canada and is characterized by severe pelvic abdominal pain, which generally peaks during menses.